Call for papers accelerates cancer information transfer - ecancermedicalscience

ecancermedicalscience aims to improve communications between sub-specialised cancer scientists and clinicians by working interactively and faster - offering authors a rapid peer review process. Submit your paper and you'll hear if it will be published within three weeks.

ecancermedicalscience (ISSN 1754-6605) is an independent online journal, publishing research articles after full peer review. All articles are published online immediately upon acceptance. The journal is published by Cancer Intelligence Ltd, Westpoint, 78 Queens Road, Clifton, Bristol, BS8 1QU.

ecancermedicalscience, founded by the European Institute of oncology, is proud to acknowledge The European CanCer Organisation as its educational and Scientific partner.

Criteria for publication
Publication of research articles by ecancermedicalscience is dependent primarily on their validity and coherence, as judged by a peer reviewer. The reviewer is asked how remarkable they consider the article to be. ecancermedicalscience is interested in publishing; innovative studies testing new hypotheses; policy research papers that challenge conventional thinking and case studies that address new and interesting ways of working.

Speed of publication
ecancermedicalscience offers fast publication whilst maintaining rigorous peer review; all articles must be submitted online, and peer review is managed electronically. A web version, and accompanying PDF, will be published within a few days of acceptance.

For further information, please visit:
http://www.ecancermedicalscience.com

Most Popular Now

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Lilly will supply an additional 150,000 doses of b…

Eli Lilly and Company (NYSE: LLY) announced a modified purchase agreement with the U.S. government to supply an additional 150,000 doses of bebtelovimab for approximately...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

Vaccine protection against COVID-19 short-lived, b…

Since COVID-19 vaccines first became available to protect against infection and severe illness, there has been much uncertainty about how long the protection lasts, and w...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

Pfizer and BioNTech advance COVID-19 vaccine strat…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the companies have initiated a randomized, active-controlled, observer-blind, Phase 2 study to...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

Scientists develop new biomimetic formulation for …

Glioblastoma multiforme (GBM) is an aggressive brain cancer with a poor prognosis and few treatment options. New and effective approaches for GBM treatment are therefore ...

New needle-free nasal vaccine shows promise for CO…

New research shows that a needle-free mucosal bacteriophage (phage) T4-based COVID-19 vaccine is effective against SARS-CoV-2 infection. The findings were published in mB...